Study patients
breast cancers
BREAST CANCER
Patients were eligible if they were female aged ≥ 18 years and diagnosed with breast cancers with an indication to receive adjuvant or neoadjuvant chemotherapy with doxorubicin. The chemotherapy regimen comprises of four cycles of doxorubicin 60 mg/m